ExploreWatchlistsPricing
  1. JP-listed companies
  2. RIBOMIC Inc.
  3. Financials
  4. Stockholders' equity

RIBOMIC Inc. (4591)

Market cap
¥3.5B
P/E ratio
-3.1x
Ribomics develops next-generation aptamer drugs using its proprietary RiboART System to treat unmet medical needs like achondroplasia and eye diseases.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndStockholders' equity (Million JPY)YoY (%)
Mar 31, 20253,044-10.26%
Mar 31, 20243,391-22.65%
Mar 31, 20234,384-6.60%
Mar 31, 20224,694-21.80%
Mar 31, 20216,003+175.23%
Mar 31, 20202,181+47.06%
Mar 31, 20191,483-33.41%
Mar 31, 20182,227-8.68%
Mar 31, 20172,439-19.75%
Mar 31, 20163,039-6.86%
Mar 31, 20153,263+821.91%
Mar 31, 2014354

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat